Herpes simplex
Not recommended
For herpes, Likopid is absent from guidelines. Proven antiherpetic agents are nucleoside analogues aciclovir, valacyclovir, and .
Other immunostimulants (local classification)
ATC code: L03AX-LIKOPID (Glucosaminyl muramyl dipeptide (Likopid) – local code)
Synthetic analogue of the minimal active fragment of bacterial cell wall (muramyl dipeptide). The manufacturer claims NOD2 receptor activation and innate immunity stimulation. The molecule is not described as a therapeutic agent in international pharmacological literature. Produced and used only in Russia by Peptek.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
For herpes, Likopid is absent from guidelines. Proven antiherpetic agents are nucleoside analogues aciclovir, valacyclovir, and .
Not recommended
Likopid is marketed as an immunomodulator for correction of secondary immunodeficiencies in frequently ill children and adults. The , , and AEMPS have not approved the drug; international clinical guidelines (, , , CDC) do not include it. Secondary immunodeficiency in frequently ill people is not recognized as an independent diagnosis in international medicine – this is often a normal cold frequency in children or social-contact factors. No independent international clinical studies exist. If Likopid was recommended, consider seeking a second opinion.
Not recommended
For recurrent URI prevention, Likopid is absent from and ERS 2023 paediatric guidelines. Evidence-based measures: influenza and pneumococcal vaccination, hand hygiene, secondhand-smoke removal, and treatment of chronic infectious foci (sinusitis, tonsillitis).
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Contraindicated in pregnancy per the manufacturer label.
Contraindicated during breastfeeding per the manufacturer label.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Glucosaminyl muramyl dipeptide is evaluated for the following indications with varying evidence strength: Herpes simplex (evidence tier F), Prevention of recurrent respiratory infections (evidence tier F), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Glucosaminyl muramyl dipeptide (≥ 1 in 100): Transient fever (common per label), Arthralgia, myalgia, Headache. See the Safety section for uncommon and serious reactions.
FDA category N. Contraindicated in pregnancy per the manufacturer label.
Contraindicated during breastfeeding per the manufacturer label.
Glucosaminyl muramyl dipeptide is contraindicated in: Pregnancy and breastfeeding; Active autoimmune disease; Fever above 38 °C; Lactose intolerance; Hypersensitivity. Full list in the Safety section.